Pricing
  1. JP-listed companies
  2. TAIKO PHARMACEUTICAL CO., LTD.
  3. Financials
  4. Total non-current liabilities

TAIKO PHARMACEUTICAL CO., LTD. (4574)

Market cap
¥15.4B
P/E ratio
27.8x
Makes over-the-counter medicines like Seirogan and Cleverin infection control products, serving consumers and institutions across Japan and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal non-current liabilities (Million JPY)YoY (%)
Dec 31, 20251,242-40.69%
Dec 31, 20242,094-39.00%
Dec 31, 20233,433-18.42%
Dec 31, 20224,208-22.17%
Dec 31, 20215,407+263.20%
Dec 31, 20201,489+14.05%
Mar 31, 20201,305+1.31%
Mar 31, 20191,288+4.16%
Mar 31, 20181,237+5.95%
Mar 31, 20171,167+0.65%
Mar 31, 20161,160+3.39%
Mar 31, 20151,122

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat